Pegylated Interferon Alfa-2b

March 2, 2025 Clinical Trials

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia

ClinicalTrials.gov ID NCT05395507
Sponsor Institute of Hematology & Blood Diseases Hospital, China

Cytokines 2026: What to Expect in Glasgow This October

May 30, 2026

With abstract notifications going out mid-June and the scientific programme taking shape, now is the time to get excited about Cytokines 2026. The meeting (18–21 October, Scottish Event Campus, Glasgow) will feature plenary and parallel sessions led by field leaders, poster sessions designed for in-depth discussion, and – new this [READ MORE]

Member Highlight: Tim Nice on Interferons, Gut Immunity, and the Joy of Uncertainty

May 30, 2026

I am Tim Nice, Associate Professor of Molecular Microbiology and Immunology at Oregon Health & Science University in Portland, OR. I grew up in rural Wisconsin and like to think that my first training as a biologist came from working with my parents to raise sheep on our farm. I [READ MORE]

New Member Mini-Bios

Welcome Hosu Kim, M.D.

May 30, 2026

I am Hosu Kim, MD. I always make a point of listening to others and learning their perspectives and habits as much as I can. At present, I am conducting translational medicine research as a full-time graduate student at the Seoul National University College of Medicine. Leveraging my research experience [READ MORE]

Welcome Biljana Riemelmoser

May 30, 2026

I am Biljana Riemelmoser, a PhD student at the University of Geneva. My research focuses on skin immunology and the function of Interleukin-38, an understudied cytokine involved in immune barrier regulation. More broadly, I am interested in how host–microbiota interactions regulate skin homeostasis and shape barrier function. I am excited [READ MORE]

Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections

May 29, 2026

ClinicalTrials.gov ID NCT06363370 Sponsor Kexing Biopharm Co., Ltd. Information provided by Kexing Biopharm Co., Ltd. (Responsible Party) Last Update Posted 2024-04-12 Brief Summary To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection. Detailed Description [READ MORE]

Biweekly newsletter of The Cytokine Society

Signals+ Editors: Daniella Schwartz & Di Yu (Editors in Chief), Saurabh Chattopadhyay, Zhian Chen, Mohamed Saad & Maialen Sebastian-delaCruz

Pegylated Interferon Alfa-2b

Share this: